Study identifier:NIS-GRS-DUM-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An epidemiological, postmarketing observational study to describe symptom control and impact of gastroesophageal reflux disease (GERD) on patients’ daily life
GERD
-
No
-
All
1000
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to examine patient's perspective of symptom control and impact of gastroesophageal reflux disease (GERD) on daily life.
Location
Location
Belgrade, Serbia
Location
Leskovac, Serbia
Location
Nis, Serbia
Location
Novi Sad, Serbia
Location
Pancevo, Serbia
Location
Subotica, Serbia
Location
Zrenjanin, Serbia
Arms | Assigned Interventions |
---|---|
1 Patients with GERD | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.